Concord Biotech Limited has informed the Exchange about General Updates- Successful Completion Of EU GMP Inspection

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.2%Reaction day

₹1696.00

prior close

₹1750.00

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.1%+3.1% vs market

Pharmaceuticals peers, median of 151sector+0.0%+3.2% vs sector

On the reaction day the stock moved 3.1 pts more than Nifty Smallcap 250 and 3.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.1

15m

-0.1

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.2+0.1+3.1+0.0+3.2

Next day

+4.2-0.1+4.3-0.2+4.5

+2.3-0.0+2.3-0.6+2.9

+0.5-1.9+2.4-1.6+2.2

-1.3-3.0+1.7-2.7+1.4

-0.8-3.3+2.4-2.3+1.5

-0.5-1.3+0.8-1.5+1.0

15d

-3.3+0.5-3.8-0.2-3.1

-4.1+1.6-5.8+0.1-4.2

-9.7+1.3-11.0-2.5-7.2

-16.1-2.0-14.1-6.5-9.6

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Concord Biotech has successfully completed its first European Union Good Manufacturing Practice (EU-GMP) inspection at its Active Pharmaceutical Ingredients (API) manufacturing facility in Limbassi, conducted from August 18 to August 21, 2025. This certification validates the company's compliance with global quality standards and opens the door for commercial expansion into EU territories and other regulated international markets. Management highlighted this as a significant milestone that strengthens the company's global growth trajectory. The facility is now positioned to explore new regulated-market opportunities for its API products.

Likely market impact

Positive for shareholders — EU GMP clearance is a key regulatory prerequisite that unlocks access to high-value European and other regulated markets, potentially supporting future revenue growth and export earnings. The stock may see a positive reaction given the strategic importance of this certification for a pharma API manufacturer.